Skip Navigation

What's new?

10-12-2014: Martindale December 2014 update

This update contains 15 new monographs and 33 existing monographs have been updated. Pharmacopoeial information has been updated to reflect Ph. Eur. 8.1 and 8.2, and preparations updated for 5 countries.

New monographs:

  • Arterolane: is a synthetic, non-artemisinin, antimalarial that is a rapidly-acting blood schizontocide. It is given with piperaquine phosphate in a fixed-dose combination for the treatment of uncomplicated falciparum malaria.
  • Asunaprevir: is an oral hepatitis C virus (HCV)-protease inhibitor effective against HCV serine protease NS3. It is used with other direct-acting antivirals in the treatment of chronic hepatitis C genotype 1 infection.
  • Brincidofovir: is a lipid conjugate prodrug of cidofovir. It is under investigation for its potential activity against a range of viruses including adenovirus, herpes simplex viruses, CMV, BK virus, and smallpox. It has also been tried in the treatment of Ebola virus infection.
  • Dulaglutide: is a fusion protein containing an analogue of the incretin hormone, glucagon-like peptide 1 (GLP-1). It acts as an agonist at the GLP-1 receptor and is used in the treatment of type 2 diabetes mellitus.
  • Ebola Virus Vaccines: several are in development.
  • Eliglustat: is an inhibitor of the enzyme glucosylceramide synthase used to help prevent the accumulation of glucosylceramide in the long-term treatment of patients with type 1 Gaucher disease.
  • Favipiravir: is a viral RNA polymerase inhibitor. It is reserved for the treatment of novel or re-emerging influenza when other anti-influenza drugs are ineffective or not sufficiently effective. Favipiravir has also been tried in the treatment of Ebola virus infection.
  • Icotinib: is an inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) that is used in the treatment of non-small cell lung cancer. It is also being investigated in the management of other solid tumours.
  • Imrecoxib: is a nonsteroidal anti-inflammatory drug reported to be a selective inhibitor of cyclo-oxygenase-2 (COX-2). It is used for the treatment of inflammation and pain associated with osteoarthritis.
  • Ledipasvir: is an oral replication inhibitor of hepatitis C virus protein NS5A that is used in a fixed-dose combination product with sofosbuvir for the treatment of chronic hepatitis C genotype 1.
  • Ligustrazine: is an alkaloid obtained from the Chinese herbal medicine chuanxiong (Ligusticum chuanxiong). It is used in the treatment of ischaemic cardiovascular disorders.
  • Lumbrokinase: describes a group of fibrinolytic enzymes isolated from extracts of Korean earthworms, Lumbricus bimastus, L. rubellus, and Eisenia fetida. Earthworm extracts have been used in traditional Far East medicines, and lumbrokinase is promoted for maintaining a healthy balance of the circulatory system. It has been investigated as an antithrombotic.
  • Naloxegol: is a peripherally-acting antagonist of opioid µ-receptors that is used for the treatment of opioid-induced constipation in patients with chronic, non-cancer pain.
  • Pembrolizumab: is a humanised immunoglobulin G4 monoclonal antibody that binds to the cell surface receptor PD-1 (programmed death-1), a negative immunoregulatory protein, thereby activating an immune response to tumour cells. It is used for the treatment of malignant melanoma.
  • Suvorexant: is an orexin-receptor antagonist used as a hypnotic in the management of insomnia.

New salts or related derivatives: Granisetron

Notable revisions:

  • Acenocoumarol: cautions and dosing updated.
  • Aflibercept: new indication and dosing for diabetic macular oedema added to uses and administration; intravitreal adverse effects updated.
  • Benzoyl Peroxide: FDA warning on hypersensitivity to topical acne preparations.
  • Ciprofloxacin: dose added for the secondary prophylaxis of meningitis in neonates.
  • Empagliflozin: monograph expanded in response to product launch in UK and USA.
  • Leuprorelin: now indicated as a neoadjuvant treatment for localised or locally advance prostate cancer in UK.
  • Metreleptin: information on adverse effects, pharmacokinetics, and uses and administration added.
  • Ponatinib: further information added on adverse effects including vascular occlusive events and ocular toxicity, and uses and administration updated.
  • Rituximab: uses and administration updated.
  • Rosuvastatin Calcium: uses and administration and interactions updated.
  • Sapropterin Hydrochloride: indications and doses updated.
  • Telaprevir: recommendations for the treatment of HCV/HIV co-infected patients with the HCV-protease inhibitors boceprevir and telaprevir added.
  • Temozolomide: adverse effects updated to include hepatotoxicity and secondary malignancies.
  • Tocilizumab: adverse effects updated, and subcutaneous dosing added.

Proprietary Preparations and Manufacturers updated for the following countries and regions: France, Japan, Portugal, UK, USA ( Countries updated on an ongoing basis)


10-9-2014: Martindale September 2014 update

This update contains 18 new monographs and 48 existing monographs have been updated. Preparations have been updated for 8 countries.

New monographs:

  • Albiglutide: is an analogue of the incretin hormone, glucagon-like peptide 1 (GLP-1). It acts as an agonist at the glucagon-like peptide 1 receptor and is used in the treatment of type 2 diabetes mellitus
  • Ataluren: is being investigated in the treatment of Duchenne muscular dystrophy and in the treatment of cystic fibrosis
  • Ceritinib: is a tyrosine kinase inhibitor that is used in the treatment of non-small cell lung cancer
  • Efinaconazole: is a triazole antifungal used topically for the treatment of onychomycosis of the toenails
  • Idelalisib: is a kinase inhibitor used in the treatment of chronic lymphocytic leukaemia, follicular B-cell non-Hodgkin's lymphoma, and small lymphocytic lymphoma
  • Ipragliflozin: is a sodium-glucose co-transporter 2 inhibitor used in the treatment of type 2 diabetes mellitus
  • Luseogliflozin: is a sodium-glucose co-transporter 2 inhibitor used in the treatment of type 2 diabetes mellitus
  • Mirodenafil: is a phosphodiesterase type-5 inhibitor used in the management of erectile dysfunction
  • Nivolumab: is a human immunoglobulin G4 monoclonal antibody used for the treatment of malignant melanoma
  • Pimavanserin: selectively interacts with serotonin 5-HT2A receptors and is being investigated for the treatment of psychosis in Parkinson's and Alzheimer's disease and for the management of schizophrenia
  • Secukinumab: is a recombinant human monoclonal interleukin-17A antibody that is under investigation for the treatment of various auto-immune or immune-mediated disorders including ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, and non-infectious uveitis
  • Siltuximab: is a chimeric murine/human monoclonal antibody that binds to and inhibits the actions of interleukin-6. It is used for the treatment of primary multicentric Castleman's disease
  • Tavaborole: is an oxaborole antifungal used topically for the treatment of onychomycosis of the toenails
  • Tebipenem pivoxil: is a carbapenem beta-lactam antibacterial similar to imipenem. It is given as the prodrug tebipenem pivoxil in the treatment of susceptible infections such as pneumonia, otitis media, and sinusitis
  • Tedizolid: is an oxazolidinone antibacterial used for the treatment of acute skin and skin structure infections caused by susceptible Gram-positive bacteria, including meticillin-resistant Staphylococcus aureus
  • Tofogliflozin: is a sodium-glucose co-transporter 2 inhibitor used in the treatment of type 2 diabetes mellitus
  • Topiroxostat: is a xanthine oxidase inhibitor and is used in the treatment of disorders associated with hyperuricaemia, including gout

Notable revisions:

  • Azathioprine: information relating to pre-treatment TPMT testing, and use in skin disorders revised
  • Brimonidine tartrate: combination product with carbonic anhydrase inhibitor added for glaucoma; topical gel licensed for erythema of rosacea
  • Carbamazepine: skin reactions and administration in children abstracts updated
  • Chloroprocaine hydrochloride: new UK preparation licensed for spinal anaesthesia
  • Complement C1 esterase inhibitor: doses updated
  • Didanosine: dose in adults and in renal impairment updated
  • Droxidopa: dose for orthostatic hypotension updated
  • Erlotinib hydrochloride: doses updated
  • Eszopiclone: doses updated
  • Etherified starches: safety information regarding use in critically ill patients updated
  • Fluorine-18: Floribetaben approved for evaluating beta-amyloid neuritic plaque density in brain patients with cognitive impairment, including Alzheimer's
  • Glyceryl trinitrate: pharmacokinetics, uses and administration, administration in children, and stability updated
  • Hydrocodone hydrochloride: interactions and overdosage information added
  • Iron sucrose: doses have been revised, including a new abstract for administration in children
  • Lurasidone: new indication of depressive phase of bipolar disorder added
  • Nonsteroidal anti-inflammatory drugs: pregnancy abstract updated
  • Oxytocin: warning on use in patients with QT interval prolongation and with drugs known to cause QT prolongation
  • Posaconazole: uses and administration updated with intravenous route and dose for the oral suspension; precautions and pharmacokinetics updated
  • Raltegravir: dose for new oral suspension formulation added
  • Ramucirumab: newly licensed for gastric and gastro-oesophageal adenocarcinoma; dosing, adverse effects, precautions, and references added
  • Riociguat: information on adverse effects and precautions, interactions, and pharmacokinetics expanded; dosing information updated
  • Soya bean: use of intravenous lipid emulsion to manage local anaesthetic cardiotoxicity updated
  • Telaprevir: new twice daily dose added; discussion on relative efficacy of bocperevir and telaprevir included; adverse effects updated to include toxic epidermal necrolysis as a severe skin reaction
  • Ulipristal acetate: UK authorities approve repetition of pre-operative course of treatment in uterine fibroids
  • Vorapaxar: newly licensed in USA for prevention of thrombosis; dosing, precautions, interactions, and pharmacokinetic information added

Proprietary Preparations and Manufacturers updated for the following countries and regions: Czech Republic, France, Hong Kong, Malaysia, New Zealand, Poland, UK, USA ( Countries updated on an ongoing basis)


11-6-2014: Martindale June 2014 update

This update contains 7 new monographs and 46 existing monographs have been updated. Preparations have been updated for 9 countries.

New monographs:

  • Apremilast: is a cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase type-4 inhibitor used in the treatment of active psoriatic arthritis. It is also under investigation for its anti-inflammatory properties in the treatment of various other auto-immune or immune-mediated disorders including ankylosing spondylitis, Behçet's syndrome, psoriasis, and rheumatoid arthritis
  • Elosulfase Alfa: is a recombinant human N-acetylgalactosamine-6-sulfatase used as enzyme replacement therapy in the treatment of mucopolysaccharidosis type IVA (Morquio A syndrome)
  • Empagliflozin: is a sodium-glucose co-transporter 2 inhibitor that is under investigation in the management of type 2 diabetes mellitus
  • Gimeracil: inhibits dihydropyrimidine dehydrogenase and reduces the metabolism of fluorouracil; it is given orally with tegafur, an orally active prodrug of fluorouracil, to increase the bioavailability of fluorouracil
  • Olodaterol Hydrochloride: is a long-acting beta2 agonist that is used in the management of chronic obstructive pulmonary disease
  • Oteracil: inhibits orotate phosphoribosyltransferase, an enzyme thought to play a role in the gastrointestinal toxicity of fluorouracil and its prodrugs; it is given orally with tegafur, an orally active prodrug of fluorouracil
  • Umeclidinium Bromide: is a quaternary ammonium antimuscarinic used as a bronchodilator in the treatment of reversible airways obstruction

Notable revisions:

  • Alitretinoin: initial doses in patients with diabetes, obesity and CV risk factors or lipid metabolism disorders updated
  • Bosutinib: new information added in administration in renal impairment
  • Clopidogrel Bisulfate: new indication for use in atrial fibrillation; adverse effects and interactions updated, including new interaction with cigarette smoking
  • Dabigatran: new indication to treat and prevent recurrence of deep-vein thrombosis and pulmonary embolism
  • Darunavir: updated dose information in children
  • Defibrotide: new indication and dosing for use in the treatment of hepatic veno-occlusive disease after HSCT
  • Dipyridamole: adverse effects on the skin added
  • Domperidone: uses and dose updated following recommendations from EMA
  • Glatiramer Acetate: new dose schedule added
  • Golimumab: new UK indication for use in ulcerative colitis added
  • Ibrutinib: new indication and dosing information for chronic lymphocytic leukemia added
  • Nepafenac: new indication to reduce the risk of macular oedema following cataract surgery added
  • Paracetamol: BNFC doses revised
  • Propranolol Hydrochloride: now licensed in the USA for infantile haemangioma
  • Sorafenib: new indication for thyroid carcinoma added
  • Tapentadol: a new modified-release preparation for the treatment of moderate to severe pain and of neuropathic pain associated with diabetic peripheral neuropathy added
  • Tasimelteon: now licensed for non-24 hour sleep wake disorder in totally blind patients

Proprietary Preparations and Manufacturers updated for the following countries and regions: Argentina, Chile, France, Hungary, Japan, Mexico, Turkey, UK, USA ( Countries updated on an ongoing basis)


12-3-2014: Martindale March 2014 update

This update contains 10 new monographs and over 150 existing monographs have been updated. Pharmacopoeial information has been updated to reflect the BP and BP Vet 2014 and Ph Eur 8.0, preparations updated for 4 countries, and information related to driving, and referenced to the UK DVLA, revised. The use of tables and figures has been expanded for this update to improve the representation of this information; a further 20 tables and 7 figures that are printed in Martindale are now also available online.

New monographs:

  • Acotiamide Hydrochloride: is an inhibitor of peripheral anticholinesterase activity; it is used in the symptomatic relief of functional dyspepsia
  • Bedaquiline: is an oral antimycobacterial that is used as part of combination therapy, with at least 3 other antituberculous drugs, in the treatment of multidrug-resistant pulmonary tuberculosis when an effective treatment regimen cannot otherwise be provided
  • Daclatasvir: is an oral replication complex inhibitor of hepatitis C virus protein NS5A that is used with other antivirals for the treatment of chronic hepatitis C
  • Ezatiostat Hydrochloride: is an inhibitor of glutathione S-transferase P1-1, and is under investigation in the treatment of myelodysplastic syndrome
  • Ibrutinib: is an inhibitor of Bruton's tyrosine kinase that is used in the treatment of mantle cell lymphoma
  • Levomilnacipran: is the 1S,2R-enantiomer of milnacipran, a serotonin and noradrenaline reuptake inhibitor. It is used as the hydrochloride for the treatment of depression
  • Macitentan: is an endothelin receptor antagonist used in the management of pulmonary hypertension
  • Simeprevir: is an oral HCV-protease inhibitor that is used in a regimen with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C genotype 1
  • Sofosbuvir: is an oral nucleotide analogue inhibitor that is used in a regimen with ribavirin, or with ribavirin and peginterferon, for the treatment of chronic hepatitis C genotypes 1, 2, 3, or 4
  • Sucroferric Oxyhydroxide: is a phosphate binder used for hyperphosphataemia in patients with chronic renal failure requiring haemodialysis

New salts or related derivatives: Nizofenone Fumarate, Pixantrone Maleate.

Notable revisions:

  • Infertility: updated guidelines from NICE and EAU
  • Malaria: updated guidelines from HPA Advisory Committee on Malaria Prevention
  • Septicaemia: updated BNF statement on treatment of community-acquired septicaemia
  • Nonsteroidal Anti-inflammatory Drugs: contraindications and warnings updated

Proprietary Preparations and Manufacturers updated for the following countries and regions: France†, Japan, UK†, USA† († Countries updated on an ongoing basis)


11-12-2013: Martindale December 2013 update

This update contains 6 new monographs, 148 existing monographs have been updated, and 3 treatment reviews re-validated. Pharmacopoeial information has been updated to reflect the USP 36 NF 31 Supplement 2, preparations updated for 9 countries, and Chinese character preparation names added.

New monographs:

  • Dabrafenib: is an inhibitor of BRAF kinases that is used for the treatment of unresectable or metastatic melanoma
  • Dolutegravir: is an HIV-integrase inhibitor that is used with other antiretrovirals for treatment of HIV infection and AIDS
  • Riociguat: is a guanylate cyclase stimulator used in the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
  • Spinosad: is an insecticide composed of a mixture of spinosad factor A and spinosad factor D in the ratio of about 5:1 and is used topically in the treatment of head lice. It is also used as an agricultural and horticultural insecticide
  • Trametinib: is an inhibitor of mitogen-activated extracellular kinases (MEK 1 and 2) that is used in the treatment of unresectable or metastatic melanoma
  • Vortioxetine: inhibits the reuptake of serotonin (5-HT) and is an antagonist at 5-HT3 and an agonist at 5-HT1A receptors. It is used in the treatment of depression

New salts or related derivatives: Esomeprazole Strontium, Lipegfilgrastim.

Notable revisions:

  • Idiopathic Thrombocytopenic Purpura: title changed to Immune Thrombocytopenia and treatment review updated
  • Non-small cell lung cancer: treatment review updated
  • Acute Lymphoblastic Leukaemia: treatment review updated
  • Paracetamol: updated advice on treatment of paracetamol poisoning
  • Aprotinin: marketing suspension lifted in EU and Canada
  • Vilanterol Trifenatate: Breo Ellipta (GSK) has its first marketing for COPD in US
  • Chapters on anthelmintics, antibacterials, and antiprotozoals: Medical Letter 2013 updates
  • Chapters on antifungals, antiprotozoals, and antivirals: US guidelines for opportunistic infections updated
  • Vaccines chapter: immunisation schedules revised and updated

Proprietary Preparations and Manufacturers updated for the following countries and regions: Finland, France†, Germany, Israel, Japan, Spain, UK†, Ukraine, USA† († Countries updated on an ongoing basis)


10-9-2013: Martindale 4th Quarter 2013 Update

Martindale updated with 62 revised and 4 new monographs

This quarter, 4 new monographs have been added and a further 62 existing monographs have been updated. In addition, 3 treatment reviews have been re-validated.

In addition, pharmacopoeial information in monographs has been updated to reflect the PhEur 7.8 and the USP 36 NF 31 Supplement 1. The Atomic Weights have also been updated.

Preparations have been updated for 7 countries, including the addition of over 6000 Chinese preparations.

Full details (PDF).


11-6-2013: Martindale 3rd Quarter 2013 Update

Martindale updated with 40 revised and 3 new monographs

This quarter, 3 new monographs have been added and a further 40 existing monographs have been updated.

In addition, pharmacopoeial information in monographs has been updated to reflect the PhEur 7.7. The ATC and ATCvet codes have also been updated.

Preparations have been updated for 7 countries.

Full details (PDF).


12-3-2013: Martindale 2nd Quarter 2013 Update

Martindale updated with 22 revised and 7 new monographs

This quarter, 7 new monographs have been added and a further 22 existing monographs have been updated.

In addition, for British Approved Names the spelling of the stem 'sulph' has been changed to 'sulf'. Pharmacopoeial information in monographs has also been updated to reflect the BP 2013, the BP (Vet) 2013, the PhEur 7.5 and 7.6, and the USP 36 and USNF 31.

Preparations have been updated for 7 countries.

Full details (PDF).


11-12-2012: Martindale 1st Quarter 2013 update

Martindale updated with 46 revised and 8 new monographs

This quarter, 8 new monographs have been added and a further 46 existing monographs have been updated.

Preparations have been updated for 6 countries.

Full details (PDF).


11-9-2012: Martindale 4th Quarter 2012 update

Martindale updated with 31 revised and 3 new monographs

This quarter, 3 new monographs have been added and a further 31 existing monographs have been updated. In addition, 7 treatment reviews have been re-validated.

Preparations have been updated for 6 countries.

Full details (PDF).


12-6-2012: Martindale 3rd Quarter 2012 update

Martindale updated with 77 revised and 2 new monographs

This quarter, 2 new monographs have been added and a further 77 existing monographs have been updated. In addition, 5 treatment reviews have been re-validated.

Preparations have been updated for 5 countries.

Full details (PDF).


22-3-2012: Martindale 2nd Quarter 2012 update

Martindale updated with 23 revised and 2 new monographs.

This quarter, 2 new monographs have been added and a further 23 existing monographs and treatment reviews have been updated.

In addition, atomic weights have been updated throughout the publication; pharmacopoeial information in monographs has also been updated to reflect the BP 2012, the BP (Vet) 2012, the PhEur 7.4 and the USP 35 and USNF 30.

Preparations have been updated for 4 countries.

Full details (PDF).


13-12-2011: Martindale 1st Quarter 2012 update

Martindale updated with 78 revised and 92 new monographs, plus 8 revised chapters or chapter sections.

This quarter, revision has been carried out on Anthelmintics, Antimalarials, General Anaesthetics, Growth Hormone and its Modulators, and also on sections of Antidiabetics, Cardiovascular Drugs, Chelators Antidotes and Antagonists, and Pharmaceutical Excipients.

In addition, 92 new monographs have been added and a further 78 existing monographs and treatment reviews have been updated. Precautions for Porphyria have been updated throughout the publication and Chinese, Greek and Japanese synonyms have also been added. Information on drugs restricted in sport has been updated for the WADA Prohibited List 2012.

Preparations have been updated for 12 countries.

Full details (PDF).


14-9-2011: Martindale 4th Quarter 2011 update

Martindale updated with 56 revised and 34 new monographs, plus 9 revised chapters or chapter sections.

This quarter, revision has been carried out on Antimigraine Drugs, Thyroid and Antithyroid Drugs, and also on sections of Analgesics Anti-inflammatory Drugs and Antipyretics, Antibacterials, Antineoplastics, Antivirals, Anxiolytic Sedatives Hypnotics and Antipsychotics, Chelators Antidotes and Antagonists, and Pharmaceutical Excipients.

In addition, 34 new monographs have been added and a further 56 existing monographs and treatment reviews have been updated. Further UNII codes have also been added to monographs. Pharmacopoeial information in monographs throughout the publication has also been updated to reflect the PhEur 7.3 and the USP 34 and USNF 29 (including supplement 2).

Preparations have been updated for 9 countries.

Full details (PDF).


16-6-2011: Martindale 3rd Quarter 2011 update

Martindale updated with 62 revised and 34 new monographs, plus 14 revised chapters or chapter sections.

This quarter, revision has been carried out on Antimyasthenics and Obstetric Drugs, and also on sections of Antibacterials, Antidiabetics, Antineoplastics, Antivirals, Anxiolytics, Cardiovascular Drugs, and Chelators Antidotes and Antagonists.

In addition, 34 new monographs have been added and a further 62 existing monographs and treatment reviews have been updated. More UNII codes have also been added to monographs. Pharmacopoeial information in monographs throughout the publication has also been updated to reflect the PhEur 7.2 and the USP 34 and USNF 29 (including supplement 1).

Preparations have been updated for 10 countries.

For this update, we have introduced the first tranche of Japanese synonyms.

Full details (PDF).


15-3-2011: Martindale 2nd Quarter 2011 update

Martindale updated with 45 revised and 16 new monographs, plus 12 revised chapters or chapter sections.

This quarter, revision has been carried out on Antigout Drugs, Antiprotozoals and Radiopharmaceuticals, and also on sections of Analgesics Anti-inflammatory Drugs and Antipyretics, Antibacterials, Anxiolytics, and Cardiovascular Drugs.

In addition, 16 new monographs have been added and a further 45 existing monographs and treatment reviews have been updated. More UNII codes have been added to monographs and the ATC and ATC(Vet) codes have updated. Pharmacopoeial information in monographs throughout the publication has also been updated to reflect the PhEur 7.1, BP 2011, BP(Vet) 2011, and updates in the 2nd supplement to the USP 33 and USNF 28.

Preparations have been updated for 8 countries.

For this update, we have introduced the first tranche of INNs in Arabic and in Chinese.

Full details (PDF).


13-12-2010: Martindale 1st Quarter 2011 update

Martindale updated with 26 new monographs, plus a new chapter section containing an additional 81 substances

This quarter, a new chapter section on `Additional Substances of Medical Interest' has been compiled of 81 substances that appear on the WADA Prohibited List and which do not appear elsewhere in Martindale.

In addition 21 other new monographs have been added to existing chapter sections and a further 53 monographs and treatment reviews have been updated. More UNII codes have been added to monographs and information on drugs restricted in sport has been updated for the WADA Prohibited List 2011. Pharmacopoeial information has also been updated to reflect the PhEur 7.0 in monographs throughout the publications.

Preparations have been updated for 7 countries

Full details (PDF).


27-9-2010: Martindale 4th quarter 2010 update

Martindale updated with 30 new monographs, plus 26 revised chapters or chapter sections

This quarter, revision has been carried out on Antidepressants, Blood Products Plasma Expanders and Haemostatics, Corticosteroids, Dermatological Drugs and Sunscreens, Disinfectants and Preservatives, General Anaesthetics, Local Anaesthetics, Miotics Mydriatics and Antiglaucoma Drugs, Muscle Relaxants, Neuromuscular Blockers, Pesticides and Repellents, Sex Hormones and their Modulators, and Vaccines Immunoglobulins and Antisera, and also on sections of Analgesics Anti-inflammatory Drugs and Antipyretics, Cardiovascular Drugs, and Supplementary Drugs and Other Substances.

In addition, 30 new monographs and treatment reviews have been added.

Preparations have been updated for 5 countries.

Full details (PDF).

For this update, we have introduced an additional drug coding system: UNII (Unique Ingredient Identifier) codes, produced by the FDA as part of the FDA/USP Substance Registration System. These codes are intended to provide a unique and unambiguous identifier for substances in drugs, biologics, foods, and devices.


22-6-2010: Martindale 3rd quarter 2010 update

Martindale updated with 13 revised and 39 new monographs, plus 11 revised chapters or chapter sections

This quarter, revision has been carried out on Antifungals, Chelators Antidotes and Antagonists, Gases, Immunosuppressants, and Stimulants and Anorectics, and also on sections of Analgesics Anti-inflammatory Drugs and Antipyretics, Antibacterials, Antineoplastics, Antivirals, Cardiovascular Drugs, and Supplementary Drugs and Other Substances.

In addition, 39 new monographs and treatment reviews have been added and a further 13 existing monographs and treatment reviews have been updated.

Preparations have been updated for 10 countries.

Full details (PDF).

For this update, we have introduced 2 additional drug coding systems: ATC codes for herbal medicines now complement the existing ATC codes for conventional and veterinary drugs; and Martindale's own unique identifiers, the Martindale codes.

The display of modification dates has been extended to most documents in Martindale. In the drug monographs, each major section now carries the date at which a change was last made. This is in addition to the revision dates currently displayed at the top of the monographs. Modification dates are also displayed in treatment reviews, preparations, and manufacturers records.

Another enhancement is to the way results are delivered when the search results are limited using the Sections or Interactions tabs. Rather than presenting the information within the full monograph, just the section requested is displayed. This should help to give a more focussed result and shorten document displays. Links to the complete monograph and to other sections are presented at the top of the document. Please let us know if you find this new presentation useful by using the Feedback form.


11-3-2010: Martindale 2nd quarter 2010 update

Martindale updated with 7 revised and 41 new monographs, plus 30 revised chapters or chapter sections

This quarter, revision has been carried out on Anthelmintics, Antiepileptics, Antihistamines, Antimalarials, Antiparkinsonian Drugs, Cough Suppressants Expectorants Mucolytics and Nasal Decongestants, Obstetric Drugs, Radiopharmaceuticals, and Stimulants and Anorectics, and also on sections of Analgesics Anti-inflammatory Drugs and Antipyretics, Antineoplastics, Antivirals, Cardiovascular Drugs, Pharmaceutical Excipients, Sex Hormones and their Modulators, and Supplementary Drugs and Other Substances.

In addition, 41 new monographs and treatment reviews have been added and a further 7 existing monographs and treatment reviews have been updated. Information on drugs in the Japanese Pharmacopoeia, 15th edition, ATC codes for veterinary drugs, and street names has been updated.

Preparations have also been updated for 7 countries.

Full details (PDF).


16-12-2009: Martindale 1st quarter 2010 update

Martindale updated with 18 revised and 48 new monographs, plus 43 revised chapters or chapter sections

This quarter, revision has been carried out on Antidiabetics and also on sections of Antibacterials, Antineoplastics, Anxiolytic Sedatives Hypnotics and Antipsychotics, Bronchodilators and Anti-Asthma Drugs, Cardiovascular Drugs, Gastrointestinal Drugs, Pharmaceutical Excipients, and Supplementary Drugs and Other Substances.

In addition, 48 new monographs have been added and a further 18 existing monographs and treatment reviews have been updated. Information on drugs restricted in sport has been updated for the WADA Prohibited List 2010.

Preparations have also been updated for 6 countries.

Full details (PDF).


10-9-2009: Martindale 4th quarter 2009 update

Martindale updated with 22 revised and 10 new monographs, plus 27 revised chapters or chapter sections

This quarter, revision has been carried out on Antiprotozoals, Contrast Media, Electrolytes, and Gases, and also on sections of Antibacterials, Antineoplastics, Anxiolytic Sedatives Hypnotics and Antipsychotics, Cardiovascular Drugs, Gastrointestinal Drugs, Pharmaceutical Excipients, and Supplementary Drugs and Other Substances.

In addition, 10 new monographs have been added and a further 22 existing monographs and treatment reviews have been updated.

Preparations have also been updated for 8 countries.

Full details (PDF).


17-6-2009: Martindale third quarter 2009 update

Martindale updated with 15 revised and 13 new monographs, plus 8 revised chapters or chapter sections

This quarter, revision has been carried out on Antimigraine Drugs, Bone Modulating Drugs, Growth Hormone and its Modulators, Nutritional Agents and Vitamins, and Thyroid and Antithyroid Drugs and also on sections of Antibacterials, Anxiolytic Sedatives Hypnotics and Antipsychotics, and Cardiovascular Drugs.

In addition, 13 new monographs have been added and a further 15 existing monographs and treatment reviews have been updated.

A new index entitled Pharmaceutical Terms in Various Languages has been included. It lists some of the commoner pharmaceutical forms and routes in English and a number of major European languages.

Preparations have also been updated for 9 countries.

Full details (PDF).


17-3-2009: Martindale second quarter 2009 update

Martindale updated with 14 revised and 9 new monographs, plus 6 chapters revised fully or in part, and updated product information for 9 countries.

This quarter, complete revision and revalidation has been carried out on Antidementia Drugs, Antigout Drugs, Antimyasthenics, and Urological Drugs, and also selected treatment reviews from Antibacterials and Cardiovascular Drugs. In addition, 9 new monographs have been added and a further 14 existing monographs and treatment reviews have been updated.

Preparations have also been updated for 9 countries.

Full details (PDF).


19-12-2008: Martindale first quarter 2009 update

Martindale updated with 22 revised and 12 new monographs, plus one fully revised chapter section, and updated product information for 10 countries.

This quarter, complete revision and revalidation of the information on Glycopeptide Antibacterials has been completed. A new chapter on Pharmaceutical Excipients has been created comprising relevant monographs from other existing chapters. In addition, 12 new monographs have been added and a further 22 existing monographs and treatment reviews have been updated.

Preparations have also been updated for 10 countries.

Full details (PDF).


19-9-2008: Martindale 4th quarter update

This quarter, 68 new monographs have been added and a further 11 have been updated, in addition to the completion of revision and revalidation of the complete database. A new feature allows easier identification of preparations with similar ingredients.

This quarter, revision and revalidation of the information on all chapters has been completed. In addition, 68 new monographs have been added and a further 11 existing monographs and treatment reviews have been updated.

Preparations have been updated for 6 countries.

A new feature added this quarter means that it is easier to identify multi-ingredient preparations with similar ingredients. The list of other preparations appears at the bottom of any multi-ingredient preparation record.

Full details (PDF).


12-6-2008: Martindale third quarter 2008 update

Martindale updated with 19 revised and 30 new monographs, plus 3 fully revised chapters, and updated product information for 8 countries.

This quarter, complete revision and revalidation of the information on Allergen Products, Angina Pectoris, Bronchodilators and Anti-asthma Drugs (complete chapter), Glatiramer Acetate, Glicofosfopeptical, Hypertension, Immunosuppressants (complete chapter), Myocardial Infarction, Nonionic Surfactants (complete chapter), Pneumonia, Reperfusion and Revascularisation, Thalidomide, and Valvular Heart Disease has been completed. In addition, 30 new monographs have been added and a further 9 existing monographs and treatment reviews have been updated.

Preparations have been updated for 8 countries including Indonesia which is new for this quarter.

Full details (PDF).


12-3-2008: Martindale second quarter 2008 update

Martindale updated with 50 revised and 45 new monographs, plus 4 fully revised chapter sections, and updated product information for 6 countries.

This quarter, 45 new monographs have been added and 50 existing monographs and treatment reviews have been updated, plus complete revision and revalidation of the information on miscellaneous Antibacterials, Beta Blockers, Hormonal Contraceptives and Hormone Replacement Therapy, and some Biologicals. Preparations have also been updated for 6 countries.

Full details (PDF).


14-12-2007: Martindale first quarter 2008 update

Martindale updated with 66 revised and 28 new monographs, including 5 fully revised chapters, and product information updated for 10 countries

This quarter, 28 new monographs have been added and 66 existing monographs and treatment reviews have been updated, including complete revision and revalidation of the information on Androgens and Anabolics, Antimycobacterials, Dermatological Drugs and Sunscreens, Nonsteroidal Anti-inflammatory Drugs, and Paraffins and Similar Bases. Preparations have also been updated for 10 countries.

We have added an alphabetical list of disease treatment reviews to the table of contents to make them easier to find.

Full details (PDF).


14-11-2007: Your views sought - please complete our 5 minute survey

MedicinesComplete User Survey - RPS Publishing is seeking important input from their customers

We are evaluating MedicinesComplete and value your input. The survey will focus on your experience at MedicinesComplete.com, its products, and other related areas (content, features, etc).

We invite you to complete this short 5 minute survey that can be accessed via the following link:

Please click here

Please be assured that your responses will be kept completely confidential within our organisation.

We ask that you please complete the survey no later than November 30, 2007.

Thank you for your time and participation.

The MC Digital Team at RPS Publishing

29-8-2007: Martindale fourth quarter 2007 update

Martindale updated with 105 revised and 19 new monographs, including 2 fully revised chapters, and product information updated for 9 countries

This quarter, 19 new monographs have been added and 105 existing monographs and treatment reviews have been updated, including complete revision and revalidation of the information on lincosamides in the chapter on Antibacterials and antiarrythmics in the chapter on Cardiovascular Drugs. Preparations have also been updated for 9 countries, including the Philippines and Poland, both new for this quarter.

Full details (PDF).


19-6-2007: Martindale third quarter 2007 update

Revised chapters, monographs, and product information

This quarter, 6 chapters or chapter sections have been completely revised and revalidated, 31 new monographs have been added, and 55 existing monographs and treatment reviews have been updated. Preparations have also been updated for 6 countries.

Drug monographs are now listed alphabetically in the contents list under Drugs and Ancillary Substances as well as by therapeutic use.

Full details (PDF).


21-3-2007: Martindale second quarter 2007 update

Revised chapters, monographs, and product information

This quarter, 5 chapters or chapter sections have been completely revised and revalidated, 21 new monographs have been added, and 40 existing monographs and treatment reviews have been updated. Preparations have also been updated for 8 countries.

Chapters on Prostaglandins and Hypothalamics have been reorganised and their contents added to new chapters on Obstetric Drugs and Growth Hormone and its Modulators.

A new printable User's Guide is now available to download from the Martindale home page.

Full details (PDF).


15-12-2006: Martindale first quarter 2007 update

Revised chapters, monographs, and product information

This quarter, information on miscellaneous analgesics, anti-inflammatory drugs, and antipyretics has been completely revised and revalidated, 63 new monographs have been added, and 76 existing monographs and treatment reviews have been updated. Preparations and manufacturer information from 12 countries has been updated, including Turkey, new for this quarter.

Full details (PDF).


25-9-2006: Martindale fourth quarter 2006 update

Revised chapters, monographs, and product information

This quarter, 46 chapters have been revised, 72 new monographs have been added, 1 new treatment review has been added, and a further 4 monographs have been updated.

Full details (PDF).


19-6-2006: Martindale third quarter 2006 update

Revised chapters, monographs, and product information

This quarter, eight chapters have been completely revised and revalidated, 10 new monographs have been added, 3 new treatment reviews have been added, and a further 6 monographs have been updated.

Full details (PDF).


23-3-2006: Martindale second quarter 2006 update

Martindale updated with new and revised monographs and new product information

This quarter, eight chapters or chapter sections have been completely revised and revalidated, 19 new monographs have been added, 3 new treatment reviews have been added, 1 new country has been added and preparations for a further 7 countries have been updated, and 31 monographs have been updated.

Full details (PDF).


15-12-2005: Martindale first quarter 2006 update

Martindale updated with new and revised monographs and new product information

This quarter, five chapters have been completely revised and revalidated, 39 new monographs and 7 new treatment reviews have been added, and a further 80 monographs have been updated. Preparations have been updated for 9 countries. In addition, pharmacopoeial information has been updated to reflect the BP 2005, USP 29, USNF 24, PhEur 5.4, and Ger.P. 2005 in monographs throughout the publication.

Full details (PDF).


11-10-2005: Martindale fourth quarter update

New and revised information, and more international names now available in Martindale

This quarter, one chapter has been completely revised and revalidated, 13 new monographs have been added, and a further 67 monographs have been updated. We have also added structural formulae to many monographs and now include the International Nonproprietary Names in Spanish, French, Russian, and Latin as well as English. ATC codes have been added to the table of contents to give another way to find information.

Full details (PDF).


28-6-2005: Martindale third quarter update

Revised chapters, monographs, and product information

The June update contains 2 completely re-evaluated chapters, 11 new drug monographs, updates to a further 97 drug and treatment monographs, and updated proprietary product information for 9 countries.

Full details (PDF).


27-5-2005: Martindale quarterly update

Revised chapters, monographs and product information.

The March update contains 2 completely re-evaluated chapters, 19 new drug monographs, updates to a further 74 drug and treatment monographs, and updated proprietary product information for 10 countries.